Alejandro Yovine, MD - AstraZeneca - VP, Global Development Lead

Alejandro Yovine

MD

AstraZeneca

VP, Global Development Lead

Cambridge, England | United Kingdom

Main Specialties: Oncology

Alejandro Yovine, MD - AstraZeneca - VP, Global Development Lead

Alejandro Yovine

MD

Introduction

Primary Affiliation: AstraZeneca - Cambridge, England , United Kingdom

Specialties:

Research Interests:

Publications

14Publications

383Reads

-Profile Views

310PubMed Central Citations

Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.

Clin Cancer Res 2013 Jul 8;19(13):3693-702. Epub 2013 May 8.

Department of Medical Oncology, INSERM Unit U981, Paris Sud University, Institut Gustave-Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0190DOI Listing
July 2013
51 Reads
73 Citations
8.722 Impact Factor

Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.

Mol Cancer Ther 2013 May 26;12(5):632-42. Epub 2013 Feb 26.

Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-0999DOI Listing
May 2013
70 Reads
20 Citations
5.683 Impact Factor

A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.

Invest New Drugs 2012 Jun 12;30(3):1193-202. Epub 2011 Apr 12.

Department of Medicine, Institut Gustave Roussy, 94805, Villejuif Cedex, France.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-011-9662-0
Publisher Site
http://dx.doi.org/10.1007/s10637-011-9662-0DOI Listing
June 2012
8 Reads
17 Citations
2.920 Impact Factor

Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas.

Invest New Drugs 2011 Dec 10;29(6):1406-13. Epub 2010 Jul 10.

Instituto Catalán de Oncología, Ctra. Gran Vía, s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-010-9488-1DOI Listing
December 2011
8 Reads
2 Citations
2.920 Impact Factor

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.

J Clin Oncol 2004 Mar;22(5):890-9

Hôpital St Louis, Unité d'Oncologie Médicale, 1 av. Claude Vellefaux, 75010 Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2004.05.210DOI Listing
March 2004
63 Citations
18.430 Impact Factor

Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.

J Clin Oncol 2001 Mar;19(5):1248-55

Hôpital Paul Brousse and Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2001.19.5.1248DOI Listing
March 2001
23 Citations
18.430 Impact Factor

Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.

Ann Oncol 2000 Nov;11(11):1463-70

Service de Cancérologie, H pital Paul Brousse, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1023/a:1026535824044DOI Listing
November 2000
5 Citations
7.040 Impact Factor